Analytical Data
-
Gene name
Serping1
- Application
-
Alternative Names
C1 esterase inhibitorC1-inhibiting factorSerpin G1
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P97290
-
Expression Region
31-503aa
-
Molecular Weight
56.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Serping1, also known as C1 inhibitor (C1-INH), is a crucial serine protease inhibitor that plays a significant role in the regulation of the complement and contact activation cascades. Its primary function is to inhibit the activity of various serine proteases, thereby preventing excessive inflammation and maintaining homeostasis within the immune system. Research into Serping1 has gained momentum due to its involvement in hereditary angioedema (HAE), a genetic disorder characterized by recurrent episodes of severe swelling, often affecting the face, extremities, and gastrointestinal tract. Mutations in the SERPING1 gene lead to either a deficiency or dysfunction of the C1 inhibitor, resulting in uncontrolled activation of the complement and coagulation pathways. Understanding the structure and function of Serping1 is critical for developing targeted therapies for HAE and other conditions associated with dysregulated protease activity. Recent advances in protein engineering and structural biology have enabled researchers to investigate Serping1 in greater detail, revealing its interaction mechanisms with serine proteases and the implications of its dysfunction in various diseases. As research continues, there is potential for innovative therapeutic approaches, including the development of recombinant Serping1 proteins and small molecule inhibitors to restore its regulatory functions or to mitigate the effects of its deficiency in affected individuals. The exploration of Serping1's role in immune regulation not only sheds light on fundamental biological processes but also opens avenues for novel treatments in immunological disorders.
